ASCENDIS ANNOUNCES ORAL PRESENTATION OF WEEK 104 DATA FROM ITS PIVOTAL TRIAL OF TRANSCON® CNP (NAVEPEGRITIDE) AT ISDS 2026

Reuters · 2d ago

Please log in to view news